Linked Life Data

19620516

Source:http://linkedlifedata.com/resource/pubmed/id/19620516

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-8-20
pubmed:databankReference
pubmed:abstractText
Insulin resistance, a key component of the metabolic syndrome, is a risk factor for diabetes mellitus and cardiovascular disease. Acetyl-L-carnitine infusion acutely ameliorated insulin sensitivity in type 2 diabetics with insulin resistance. In this sequential off-on-off pilot study, we prospectively evaluated the effects of 24-week oral acetyl-L-carnitine (1 g twice daily) therapy on the glucose disposal rate (GDR), assessed by hyperinsulinemic euglycemic clamps, and components of the metabolic syndrome in nondiabetic subjects at increased cardiovascular risk a priori segregated into 2 groups with GDR < or =7.9 (n=16) or >7.9 (n=16) mg/kg per minute, respectively. Baseline GDR and systolic blood pressure were negatively correlated (n=32; P=0.001; r=-0.545), and patients with GDR < or =7.9 mg/kg per minute had higher systolic/diastolic blood pressure than those with higher GDR. Acetyl-L-carnitine increased GDR from 4.89+/-1.47 to 6.72+/-3.12 mg/kg per minute (P=0.003, Bonferroni-adjusted) and improved glucose tolerance in patients with GDR < or =7.9 mg/kg per minute, whereas it had no effects in those with higher GDRs. Changes in GDR were significantly different between groups (P=0.017, ANCOVA). Systolic blood pressure decreased from 144.0+/-13.6 to 135.1+/-8.4 mm Hg and from 130.8+/-12.4 to 123.8+/-10.8 mm Hg in the lower and higher GDR groups, respectively (P<0.05 for both; P<0.001 overall) and progressively recovered toward baseline over 8 weeks posttreatment. Total and high molecular weight adiponectin levels followed specular trends. Diastolic blood pressure significantly decreased only in those with higher GDRs. Treatment was well tolerated in all of the patients. Acetyl-L-carnitine safely ameliorated arterial hypertension, insulin resistance, impaired glucose tolerance, and hypoadiponectinemia in subjects at increased cardiovascular risk. Whether these effects may translate into long-term cardioprotection is worth investigating.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1524-4563
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
567-74
pubmed:dateRevised
2010-1-21
pubmed:meshHeading
pubmed-meshheading:19620516-Acetylcarnitine, pubmed-meshheading:19620516-Adiponectin, pubmed-meshheading:19620516-Administration, Oral, pubmed-meshheading:19620516-Adult, pubmed-meshheading:19620516-Blood Glucose, pubmed-meshheading:19620516-Blood Pressure, pubmed-meshheading:19620516-Cardiovascular Diseases, pubmed-meshheading:19620516-Double-Blind Method, pubmed-meshheading:19620516-Drug Administration Schedule, pubmed-meshheading:19620516-Female, pubmed-meshheading:19620516-Glucose Tolerance Test, pubmed-meshheading:19620516-Humans, pubmed-meshheading:19620516-Hypertension, pubmed-meshheading:19620516-Insulin Resistance, pubmed-meshheading:19620516-Leptin, pubmed-meshheading:19620516-Male, pubmed-meshheading:19620516-Middle Aged, pubmed-meshheading:19620516-Prospective Studies, pubmed-meshheading:19620516-Treatment Outcome, pubmed-meshheading:19620516-Vitamin B Complex, pubmed-meshheading:19620516-Young Adult
pubmed:year
2009
pubmed:articleTitle
Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy.
pubmed:affiliation
Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, Bergamo, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't